驱虫药相关的专利数据

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
181	Anthelmintika	EP90810711.3	1990-09-18	EP0420805A3	1991-10-16	Maienfisch, Peter, Dr.; Hildenbrand, Christof, Dr.; Gehret, Jean-Claude, Dr.
Es wurden anthelmintisch aktive Verbindungen der Formel I beschrieben worin R₁ für Wasserstoff, Halogen, C₁-C₂-Alkyl, C₁-C₂-Haloalkyl, Nitro, C₁-C₂-Alkoxy oder für die Gruppe SO_nR steht, worin R C₁-C₂-Alkyl oder Phenyl bedeutet und n für 0, 1 oder 2 steht; R₂ für Wasserstoff, Halogen, C₁-C₂-Alkyl, C₁-C₂-Haloalkyl, C₁-C₂-Haloalkoxy oder C₁-C₂-Alkoxy steht; R₃ Wasserstoff oder C₁-C₂-Alkyl bedeutet; R₄ Wasserstoff oder C₁-C₂-Alkyl bedeutet; R₅ für Wasserstoff, Halogen oder C₁-C₅-Alkyl steht; R₆ für Wasserstoff, Halogen oder C₁-C₅-Alkyl steht; R₇ Wasserstoff, Halogen, C₁-C₂-Alkyl, Nitro, C₁-C₂-Haloalkyl, C₁-C₂-Haloalkoxy oder C₁-C₂-Alkoxy bedeutet; R₈ Wasserstoff, Halogen, C₁-C₂-Alkyl, C₁-C₂-Haloalkyl, C₁-C₂-Haloalkoxy oder C₁-C₂-Alkoxy bedeutet; R₉ Wasserstoff, Halogen, C₁-C₂-Alkyl, C₁-C₂-Haloalkyl, C₁-C₂-Haloalkoxy oder C₁-C₂-Alkoxy bedeutet; R₁₀ für Wasserstoff, Halogen, Nitro, NCS, OCF₃, C₁-C₂-Alkyl oder C₁-C₂-Alkoxy steht; R₁₁ für Wasserstoff, Halogen, Nitro, NCS, OCF₃, C₁-C₂-Alkyl oder C₁-C₂-Alkoxy steht; oder R₁₀ und R₁₁ zusammen eine -O(CH₂)_mO-brücke bilden, wobei m für 1, 2 oder 3 steht, unter Einschluss ihrer physiologisch verträglichen Säureadditionssalze, sowie deren Herstellung und Verwendung und neue Zwischenprodukte.
182	Anthelmintika	EP83810351.3	1983-08-08	EP0101412B1	1989-03-29	Boray, Joseph C., Dr.

183	Anthelmintika	EP90810710.5	1990-09-18	EP0420804A3	1991-11-27	Maienfisch, Peter, Dr.; Hildenbrand, Christof, Dr.; Gehret, Jean-Claude, Dr.
Es wurden anthelmintisch aktive Verbindungen der Formel I beschrieben worin R₁ für Wasserstoff, Halogen, C₁-C₂-Alkyl, C₁-C₂-Thioalkyl, C₁-C₂-Haloalkyl, Nitro, C₁-C₂-Alkoxy oder für die Gruppe SO_nR steht, worin R C₁-C₂-Alkyl oder Phenyl bedeutet und n für 0, 1 oder 2 steht; R₂ für Wasserstoff, Halogen, C₁-C₂-Alkyl, C₁-C₂-Haloalkyl, C₁-C₂-Haloalkoxy oder C₁-C₂-Alkoxy steht; R₃ Wasserstoff oder C₁-C₂-Alkyl bedeutet; R₄ Wasserstoff oder C₁-C₂-akkyl bedeutet; R₅ für Wasserstoff, Halogen oder C₁-C₅-Alkyl steht; R₆ für Wasserstoff, Halogen oder C₁-C₅-Alkyl steht; R₇ Wasserstoff, Halogen, C₁-C₂-Alkyl, Nitro, C₁-C₂-Haloalkyl, C₁-C₂-Haloalkoxy oder C₁-C₂-Alkoxy bedeutet; R₈ Wasserstoff, Halogen, C₁-C₂-Alkyl, C₁-C₂-Haloalkyl, C₁-C₂-Haloalkoxy oder C₁-C₂-Alkoxy bedeutet; R₉ Wasserstoff, Halogen, C₁-C₂-Alkyl, C₁-C₂-Haloalkyl, C₁-C₂-Haloalkoxy oder C₁-C₂-Alkoxy bedeutet; R₁₀ für Wasserstoff, Halogen, C₁-C₆-Alkyl, C₁-C₂-Haloalkyl, C₁-C₂-Alkylthio, C₃-C₆-Cycloalkyl oder Cyano steht; R₁₁ für Wasserstoff, Halogen, C₁-C₆-Alkyl, C₁-C₂-Haloalkyl, C₁-C₂-Alkylthio, oder C₃-C₆-Cycloalkyl steht; R₁₂ für Wasserstoff oder Halogen steht; und Y =CH- oder =N- repräsentiert; unter Einschluss ihrer physiologisch verträglichen Säureadditionssalze, sowie deren Herstellung und Verwendung und neue Zwischenprodukte.
184	Anthelminthika	EP90810905.1	1990-11-22	EP0430883A3	1991-11-06	Molleyres, Louis-Pierre, Dr.; Gallay, Jean-Jacques, Dr.
Es werden neue Anthelminthika beschrieben, die als Wirkstoff eine Verbindung der Formel I oder in ihrer hydrierten Form der Formel la aufweisen, worin R₁ und R₂ unabhängig voneinander für C₁-C₆-Alkyl, Allyl, C₃-C₆-Cycloalkyl, Benzyl oder Phenyl stehen; und R_s für ein unsubstituiertes oder substituiertes, über Kohlenstoff gebundenes, heteroaromatisches Fünfringazol steht, ausgewählt aus der Reihe Benzimidazol, Benzoxazol, Benzthiazol, Imidazol, Oxazol, Thiazol, Oxadiazol, Thiadiazol, und Triazol; und R₄ und R_s unabhängig voneinander Wasserstoff, C₁-C₆-Alkyl, C₁-C₆-Haloalkyl, Ci-C₆-Alkoxy oder C₁-C₆-Haloalkoxy bedeuten, unter Einschluss ihrer tautomeren Formen und physiologisch verträglichen Salze, enthalten. Es wird auch die Herstellung, Formulierung und Verwendung dieser Wirkstoffe beschrieben.
185	Anthelmintika	EP90810641.2	1990-08-23	EP0415889A2	1991-03-06	Molleyres, Louis-Pierre, Dr.
Es werden neue Anthelmintika beschrieben, die als Wirkstoff eine Verbindung der Formel I oder in ihrer hydrierten Form der Formel Ia worin R₁ und R₂ unabhängig voneinander für C₁-C₆-Alkyl, Allyl, C₃-C₆-Cycloalkyl oder Phenyl stehen; und R₃ für unsubstituiertes oder ein- oder mehrfach substituiertes Phenyl, Biphenylyl oder Phenoxyphenyl steht; wobei deren Substituenten ausgewählt sind aus der Gruppe Halogen, Cyano, C₁-C₃-Alkyl, C₁-C₃-Haloalkyl, C₁-C₃-Alkoxy, C₁-C₃-Haloalkoxy, C₁-C₃-Cyanoalkyl, Nitro, Amino oder durch C₁-C₃-Alkoxycarbonyl substituiertes C₁-C₃-Alkyl, unter Einschluss deren tautomeren Formen und physiologisch verträglichen Salze, enthalten. Es wird auch die Herstellung, Formulierung und Verwendung dieser Wirkstoffe beschrieben.
186	Anthelmintika	EP82810112.1	1982-03-12	EP0060810B1	1984-10-17	Boray, Joseph Coleman, Dr.

187	Anthelmintic oral homogeneous veterinary pastes	US11107048	2005-04-15	US07563773B2	2009-07-21	Keith Freehauf; Maryam Moaddeb
This invention provides for, inter alia, oral homogeneous veterinary pastes for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals or birds, such as horses and household pets. This invention further provides for a process of preparing these veterinary pastes and for a method for increasing the bioavailability of the anthelmintic agents contained in the paste in the warm-blooded animal or bird. The inventive oral homogeneous anthelmintic pastes comprise a first anthelmintic agent, for example, prazequantel and/or pyrantel, and at least one marcrolide anthelmintic compound, a solvent, which dissolves both the first anthelmintic agent and second the macrolide anthelmintic compound, and a thickening agent. The inventive oral homogeneous pastes achieve a better bioavailability of the two active anthelmintic agents than when the two actives are in suspension and not dissolved
188	Anthelmintic oral homogeneous veterinary pastes	US11107048	2005-04-15	US20050176657A1	2005-08-11	Keith Freehauf; Maryam Moaddeb
This invention provides for, inter alia, oral homogeneous veterinary pastes for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals or birds, such as horses and household pets. This invention further provides for a process of preparing these veterinary pastes and for a method for increasing the bioavailability of the anthelmintic agents contained in the paste in the warm-blooded animal or bird. The inventive oral homogeneous anthelmintic pastes comprise a first anthelmintic agent, for example, prazequantel and/or pyrantel, and at least one marcrolide anthelmintic compound, a solvent, which dissolves both the first anthelmintic agent and second the macrolide anthelmintic compound, and a thickening agent. The inventive oral homogeneous pastes achieve a better bioavailability of the two active anthelmintic agents than when the two actives are in suspension and not dissolved
189	Bengamide anthelmintics	US875486	1986-06-18	US4831135A	1989-05-16	Philip Crews; Thomas R. Matthews; Emilio Quinoa; Madeline Adamczeski
Novel .delta.-caprolactam derivatives of formula I have anti-tumor, antibiotic and anthelmintic activity: ##STR1## wherein: R is H, lower alkyl, or lower acyl;R.sub.1, R.sub.2, and R.sub.3 are each independently H or lower acyl;R.sub.4 is H or acyl of 1 to 22 carbon atoms;R.sub.5 is H or lower acyl;R.sub.6 and R.sub.7 are each H or OH, or R.sub.6 and R.sub.7 together form an epoxide or a double bond;and the pharmaceutically acceptable salts thereof.
190	Anthelmintic benzimidazoles	US941997	1978-09-13	US4174400A	1979-11-13	Helmut Mrozik
Benzimidazole compounds are disclosed which are substituted at the 2-position with a loweralkoxy carbonylamino group and at the 5-position with a halogenated loweralkenyl group or a halogenated loweralkoxy, loweralkylthio, loweralkylsulfinyl or loweralkylsulfonyl. Processes for the preparation of such compounds are disclosed. The compounds are active anthelmintic agents and compositions for such use are also disclosed.
191	Anthelmintic oral homogeneous veterinary pastes	US10177822	2002-06-21	US20030236203A1	2003-12-25	Keith Freehauf; Maryam Moaddeb
This invention provides for, inter alia, oral homogeneous veterinary pastes for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals or birds, such as horses and household pets. This invention further provides for a process of preparing these veterinary pastes and for a method for increasing the bioavailability of the anthelmintic agent contained in the paste in the warm-blooded animal or bird. The inventive oral homogeneous anthelmintic pastes comprise a first anthelmintic agent, for example, prazequantel and/or pyrantel, and at least one marcrolide anthelmintic compound, a solvent, which dissolves both the first anthelmintic agent and second the macrolide anthelmintic compound, and a thickening agent. The inventive oral homogeneous pastes achieve a better bioavailability of the two active anthelmintic agents than when the two actives are in suspension and not dissolved
192	Anthelmintics effective against liver flukes	US724785	1976-09-20	US4034110A	1977-07-05	Milan Mitrovic; Terence James Hayes
A method is disclosed for controlling liver fluke infections comprising orally administering to host animals an anthelmintically effective amount of a compound selected from a group of halogen-substituted-benzenesulfonanilides represented by the formula: ##STR1## wherein each of R.sub.1 and R.sub.2 are independently chlorine or bromine, R.sub.3 is hydrogen or chlorine and each of R.sub.4 through R.sub.7 is independently hydrogen, halogen or trifluoromethyl, with the proviso that at least 2 of R.sub.3 through R.sub.7 is other than hydrogen and X is hydrogen or lower alkanoyl.
193	ANTHELMINTIC FORMULATIONS	EP94924428	1994-08-22	EP0724437A4	1998-07-29	HARVEY COLIN MANSON
This invention relates to anthelmintic compositions and has particular application to injectable compositions containing closantel together with an avermectin or milbemycin such as moxidectin, ivermectin, doramectin Milbemycin D, or other milbemycins together with a glycol based solvent such as polyethylene glycol or propylene glycol. The formulations may also include trace elements and/or vitamins.
194	ANTHELMINTIC FORMULATIONS	EP05790713.1	2005-09-15	EP1940396A1	2008-07-09	RAZZAK, Majid Hameed Abdul
This invention relates to the preparation of veterinary anthelmintic formulations including triclabendazole in solution, particularly for the treatment of parasitic infections such as fasciolisis, and particularly for administration to an animal in the form of a pour-on. The solutions include triclabendazole dissolved in a solvent system including at least one solvent selected from 2-pyrrolidone and liquid polyethylene glycol. Additional solvents may also be included. The present invention is advantageous as triclabendazole can be included in solution up to a concentration of about 60% w/v allowing for an effective dose to be delivered to the animal in a volume of 25 ml or less.
195	Anthelmintic preparations	EP83102982.2	1983-03-25	EP0090368B1	1987-09-02	Ganley, John Anthony; McBeath, David George; McTaggart, Celia Margaret; Wells, Peter William

196	スルホンアミド駆虫薬	JP2014543484	2012-11-07	JP2015502936A	2015-01-29	ジョージ・フィリップ・ラーム; モウミタ・カール
式1【化1】の化合物、そのN−オキシドおよび塩(式中、Q、A、R1、R2、R3およびnは本開示中において定義されているとおりである)。また、式1の化合物を含有する組成物、および、殺寄生虫的に有効な量の本発明の化合物または組成物を動物に投与するステップを含む蠕虫感染の処置方法もまた開示されている。
197	Anthelmintics effective against liver flukes	US775064	1977-03-07	US4123553A	1978-10-31	Milan Mitrovic; Terence J. Hayes
A method is disclosed for controlling liver fluke infections comprising orally administering to host animals an anthelmintically effective amount of a compound selected from a group of halogen-substituted-benzenesulfonanilides represented by the formula: ##STR1## wherein each of R.sub.1 and R.sub.2 are independently chlorine or bromine, R.sub.3 is hydrogen or chlorine and each of R.sub.4 through R.sub.7 is independently hydrogen, halogen or trifluoromethyl, with the proviso that at least 2 of R.sub.3 through R.sub.7 is other than hydrogen and X is hydrogen or lower alkanoyl.
198	ANTHELMINTIC FORMULATIONS	EP05790713	2005-09-15	EP1940396A4	2009-11-11	RAZZAK MAJID HAMEED ABDUL

199	ANTHELMINTIC FORMULATIONS	EP94924428.0	1994-08-22	EP0724437A1	1996-08-07	HARVEY, Colin, Manson
This invention relates to anthelmintic compositions and has particular application to injectable compositions containing closantel together with an avermectin or milbemycin such as moxidectin, ivermectin, doramectin Milbemycin D, or other milbemycins together with a glycol based solvent such as polyethylene glycol or propylene glycol. The formulations may also include trace elements and/or vitamins.
200	ANTHELMINTIC FORMULATIONS	EP05790713.1	2005-09-15	EP1940396B1	2011-07-06	RAZZAK, Majid Hameed Abdul
This invention relates to the preparation of veterinary anthelmintic formulations including triclabendazole in solution, particularly for the treatment of parasitic infections such as fasciolisis, and particularly for administration to an animal in the form of a pour-on. The solutions include triclabendazole dissolved in a solvent system including at least one solvent selected from 2-pyrrolidone and liquid polyethylene glycol. Additional solvents may also be included. The present invention is advantageous as triclabendazole can be included in solution up to a concentration of about 60% w/v allowing for an effective dose to be delivered to the animal in a volume of 25 ml or less.

5 6 7 8 9 10 11 12 13 14

IPRDB

热门服务

关于我们

友情链接

联系方式